Study of Daily Indapamide Treatment for 14 Days in Adults with Long-Term Post-Surgical Hypoparathyroidism

What this Trial Is About

This research aims to study the effects of daily treatment with Indapamide on urinary calcium levels in patients who have post-surgical hypoparathyroidism. The trial focuses on patients diagnosed with this condition more than a year ago and evaluates how Indapamide influences calcium excretion compared to a placebo. The study is a randomized, triple-blind Phase 4 trial designed to provide insights into managing calcium levels in this specific patient group. Participants will receive either Indapamide 1.5 mg daily or a placebo for 14 days. The trial includes two study arms one with the active drug Indapamide and the other with placebo treatment, each lasting for 14 days. The treatments are taken daily, and participants are monitored closely throughout the treatment period to assess the drugs effect on calcium excretion. During the study, participants will undergo weekly blood sampling and collect 24-hour urine samples every two weeks to monitor calcium and other relevant blood levels. Researchers will measure urinary calcium excretion on day 15 as the primary outcome, along with ionized calcium levels, sodium diet, and blood pressure safety assessments. The study runs from August 2025 to December 2025, with careful safety monitoring and follow-up throughout the trial period.

Treatment With Indapamide in Patients With Post-Surgical Hypoparathyroidism